GlaxoSmithKline and NeuroMetrix to develop wearable pain relief products

GlaxoSmithKline has entered a new global partnership with NeuroMetrix to develop and commercialise a line of wearable pain relief products.

The collaboration will see the companies joining forces to develop and expand access to Quell, a drug-free system that can be worn during the day and night for the management of chronic pain, and also offers health tracking features that can monitor pain, sleep, activity and gait data.

Under the terms of the deal, GlaxoSmithKline Consumer Healthcare will acquire exclusive ownership of Quell technology for markets outside the US, with NeuroMetrix retaining control of the brand in the US market.

The companies will co-fund development of Quell technology for a three-year period beginning in 2018 and ending in 2020, with subsequent annual renewals by mutual agreement.

Dr Shai Gozani, president and chief executive officer of NeuroMetrix, said: "We believe that GlaxoSmithKline is our ideal Quell partner, as we share a deep commitment to science-based therapies and to the health and quality of life of our customers."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.